Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310579 | 0.90 | ALDH1A1 (0.42) | RXFP1LTA4HOPRD1SIGMAR1MAOB | |
| SCHEMBL27724136 | 0.78 | ALDH1A1 (0.48) | SIGMAR1ALDH1A1SCN9A | |
| SCHEMBL3696856 | 0.77 | OPRD1 (0.41) | LTA4HOPRD1MAOBCD274ALDH1A1 | |
| SCHEMBL1189609 | 0.76 | LTA4H (0.44) | LTA4HOPRD1SIGMAR1ALDH1A1 | |
| SCHEMBL9678086 | 0.74 | LTA4H (0.43) | LTA4HOPRD1SIGMAR1MAOBALDH1A1 | |
| SCHEMBL24532343 | 0.73 | PDK1 (0.46) | LTA4HSIGMAR1 | |
| SCHEMBL3234426 | 0.73 | ALDH1A1 (0.43) | MAOBALDH1A1NPC1HTTRAB9A | |
| SCHEMBL6132926 | 0.73 | PDK1 (0.46) | LTA4HSIGMAR1 | |
| SCHEMBL6133192 | 0.73 | PDK1 (0.46) | LTA4HSIGMAR1 | |
| SCHEMBL5650658 | 0.73 | SCN9A (0.47) | ALDH1A1NPC1HTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, HAMP | RXFP1 2625/4885LTA4H 1603/4885OPRD1 4108/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | RXFP1 1114/4885LTA4H 1220/4885OPRD1 4021/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | RXFP1 1600/4885LTA4H 1769/4885OPRD1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.